These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38264058)

  • 21. The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
    Futami M; Suzuki K; Kato S; Ohmae S; Tahara Y; Nojima M; Imai Y; Mimura T; Watanabe Y; Tojo A
    PLoS One; 2020; 15(4):e0231896. PubMed ID: 32320454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies.
    Saiz LC; Leache L; Gutiérrez-Valencia M; Erviti J; Rojas Reyes MX
    Ther Adv Hematol; 2023; 14():20406207231168211. PubMed ID: 37138698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
    Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
    Guo M; Wang X; Xiao S; Liu A; Xu T; Huan C; Wu H; Hu Y; Zhou S; Zhu H; Pan D
    Clin Exp Med; 2023 Oct; 23(6):2041-2050. PubMed ID: 36930381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
    Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
    [No Abstract]   [Full Text] [Related]  

  • 29. Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
    Wang X; Zhao L; Wang J; Yao Y; Wang J; Ji S; Hua T; Wang S; Cheng H; Shi M; Li Z; Zeng L; Zheng J; Xu K; Cao J
    Front Immunol; 2022; 13():814548. PubMed ID: 35572513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden.
    Patel R; Patel M; Laxmidhar F; Lakhatariya K; Patel D; Patel Z; Shaikh S
    Cureus; 2023 Nov; 15(11):e49452. PubMed ID: 38152777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
    Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
    Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
    Xiang X; He Q; Ou Y; Wang W; Wu Y
    Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS.
    Zhang M; Long X; Xiao Y; Jin J; Chen C; Meng J; Liu W; Liu A; Chen L
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine Release Syndrome after Chimeric Antigen Receptor Transduced T-Cell Therapy in Cancers: A Systematic Review.
    Taheri S
    Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):795-823. PubMed ID: 38018721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
    Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
    Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
    Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia.
    Mao Y; Xu X
    Ann Clin Lab Sci; 2021 Nov; 51(6):790-794. PubMed ID: 34921032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.
    Singh N; Hofmann TJ; Gershenson Z; Levine BL; Grupp SA; Teachey DT; Barrett DM
    Cytotherapy; 2017 Jul; 19(7):867-880. PubMed ID: 28506444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
    Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.